Browsed by
Tag: Pomerantz

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioMarin Pharmaceuticals, Inc. of

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioMarin Pharmaceuticals, Inc. of

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on
their Investment in BioMarin Pharmaceuticals, Inc. of Class Action Lawsuit and
Upcoming Deadline – BMRN

NEW YORK, Oct.  08, 2020 (GLOBE  NEWSWIRE) -- Pomerantz  LLP announces that  a
class action lawsuit  has been  filed against  BioMarin Pharmaceuticals,  Inc.
 (“BioMarin” or the “Company”)  (NASDAQ: BMRN) and  certain of its  officers. 
The class  action, filed  in United  States District  Court for  the  Northern
District of California,  and docketed  under 20-cv-06719,  is on  behalf of  a
class consisting  of  all  persons  other than  Defendants  who  purchased  or
otherwise, acquired BioMarin securities between  February 28, 2020 and  August
18, 2020,  both  dates inclusive  (the  “Class Period”),  seeking  to  recover
damages caused by Defendants’ violations of the federal securities laws and to
pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange  Act
of 1934 (the “Exchange  Act”) and Rule  10b-5 promulgated thereunder,  against
the Company and certain of its top officials.

If you are a  shareholder who purchased BioMarin  securities during the  class
period, you have until November 24, 2020,  to ask the Court to appoint you  as
Lead Plaintiff for  the class.  A  copy of  the Complaint can  be obtained  at
www.pomerantzlaw.com.  To discuss this action, contact Robert S. Willoughby at
newaction@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.  7980.
Those who inquire by e-mail are  encouraged to include their mailing  address,
telephone number, and the number of shares purchased. 

         [Click here for information about joining the class action]

BioMarin is a biotechnology company that develops and commercializes therapies
for people  with  serious  and  life-threatening  rare  diseases  and  medical
conditions.  The   Company’s  product   candidates  include,   among   others,
valoctocogene roxaparvovec, an investigational adeno-associated virus  (“AAV”)
gene therapy, which is  in Phase 3 clinical  development for the treatment  of
patients with severe hemophilia A.

Based 
Read the rest